P/E ratio for Agenus (AGEN)
P/E ratio as of September 2023 (TTM): -1.39
According to Agenus 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.39412. At the end of 2017 the company had a P/E ratio of -2.67.
P/E ratio history for Agenus from 2001 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2017 | -2.67 | -4.66% |
| 2016 | -2.80 | -29.01% |
| 2015 | -3.95 | -33.37% |
| 2014 | -5.93 | 158.11% |
| 2013 | -2.30 | -72.56% |
| 2012 | -8.37 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 32.1 | -2,401.67% | 🇺🇸 USA |
 Merck MRK | 86.1 | -6,278.10% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 15.6 | -1,219.69% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 4.52 | -424.07% | 🇬🇧 UK |
 Celldex Therapeutics CLDX | -11.1 | 699.49% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.